Navigation Links
Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Date:8/19/2007

Multi-Center International Study to Determine the Efficacy of LBH589 in

Patients with Relapsed or Refractory Multiple Myeloma

NORWALK, Conn., Aug. 14 /PRNewswire-USNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) today announced its participation in a Phase II study to determine the efficacy of LBH589 for the treatment of patients with relapsed or refractory multiple myeloma. LBH589 is an orally administered deacetylase inhibitor developed by Novartis Pharmaceuticals.

The MMRC is the only research model of its kind bringing together 13 leading academic institutions to accelerate the development of novel and combination treatments for multiple myeloma, an incurable cancer of the plasma cell. In addition to its most recent partnership with Novartis, the MMRC is facilitating several other clinical trials, including a Phase I study of NPI- 0052, a proteasome inhibitor, in collaboration with Nereus Pharmaceuticals, and a Phase I study of perifosine, lenalidomide (REVLIMID(R)), and dexamethasone in collaboration with Keryx Biopharmaceuticals.

"Deacetylase inhibitors may represent a new treatment options for cancer patients and the MMRC is proud to work with Novartis to advance this important clinical program," said Kathy Giusti, Founder and Chief Executive Officer of the MMRC, as well as a myeloma patient. "This trial and the others the MMRC is facilitating demonstrate the importance of novel collaborations in bringing new treatments to patients."

Named ALPHA-MM, this trial is a single arm, open label, multi-center global study that will enroll 144 patients in the United States, Canada, and Europe. MMRC Member Institutions that will enroll patients are Dana-Farber Cancer Institute, City of Hope National Medical Center, Emory University, Hackensack University Medical Center, Mayo Clinic, H. Lee Moffitt Cancer Center & Research Institute, and Washington University.

This trial is open to patients with relapsed or r
'/>"/>

SOURCE The Multiple Myeloma Research Consortium

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Gentiums Defibrotide Seen as Active in Multiple Myeloma
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
7. CytRx Announces Clinical Results from Its Rising Multiple Dose Trial with Arimoclomol for ALS
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
10. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
11. Orchestra Therapeutics Announces New Phase II Clinical Data on NeuroVax Demonstrating Marked Expansion of Regulatory T Cell Populations in Patients With Multiple Sclerosis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)..., NEW YORK, Nov. 20 Reportlinker...s available in its catalogue. ,, Global Market...http://www.reportlinker.com/p0164742/Global-Market...source=prnewswire&utm_medium=pr&utm_campai...Reproduction covers the U.S., 15 Countries in Euro...
(Date:11/20/2009)...NNEAPOLIS, Nov. 20 Biote...s for its first quarter ended September 30, 2009 w... share, on revenues of $3,263,000. This compares ...share, on revenues of $3,168,000 for the first qua...uarter results, Biotel President and CEO Steve Spr...
(Date:11/20/2009)...RANKLIN LAKES, N.J., Nov. 20 /PRNewswire-FirstCall...DX ) today announced the completion of its acquisi...ed company that develops and manufactures molecula..., In May 2009, BD and HandyLab announced an exclus...molecular assays on the HandyLab Jaguar(TM) platfo...
Breaking Medicine Technology:Reportlinker Adds Global Markets for Assisted Reproductive Devices 2009 2Biotel Announced Profitable First Quarter Ended September 30, 2009 2BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 1Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 2Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 3Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 4Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 5Sanofi Pasteur Begins Shipments of Fluzone 28R 29 Influenza Virus Vaccine for 2009 2010 Seasonal Influenza 52839 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 1Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 2Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 3Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 4Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 5Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 6Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis 28PMO 29 13216 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 1Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 2Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 3Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 4Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 5Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 6Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 7Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 8Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 9Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 10Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 11Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 12Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 13Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 14Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 15Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 16Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 17Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 18Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 19Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 20Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 21Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 22Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 23Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 24Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 25Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 26Amgens Second Quarter 2009 Adjusted Earnings Per Share Increased 13 Percent To 241 29 52833 27
...study appearing in the March,22 New England Journa...l Institutes of Healths National Institute of Arth...) have discovered a,connection between a specific ... as well as a possible host of autoimmune,diseases...ocytes (the cells,that make pigment) in the skin a...
...l utilization management,programs, ST. PAUL, Minn....manager Prime Therapeutics (Prime) today announced...ttera(R) (atomoxetine) for treating,attention defi...,study found that children who start on Strattera ... than children who started on,stimulants. Due to t...
Other Medicine Technology:Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 2Scientists Implicate Gene in Vitiligo and Other Autoimmune Diseases 3Study Shows Children With ADHD Who Start on Strattera are More,Likely to Change Therapies 2Study Shows Children With ADHD Who Start on Strattera are More,Likely to Change Therapies 3
(Date:11/21/2009)... Eric J. Hall, president and chief execut...ca (AFA) issued the following statement regarding ... part of the new annual wellness for Medicare bene...rdable Care Act" that was introduced last nig...) November 21, 2009 -- Eric J. Hall, president and...
(Date:11/20/2009)...CETON, NJ, Nov. 20 /PRNewswire-FirstCall/ - NUCRYS...cial Meeting of Shareholders will be held on Monda...s to consider approval of two special resolutions....thorize the sale of all or substantially all of th...ovided for in the asset purchase agreement dated N...
(Date:11/20/2009)... Senators and Congressmen in Competitive ... Health Care Vote , Washi...d congressmen running for re-election next year in...Charlie Cook, may come to regret voting for House ...ording to a breaking Zogby International/ O’...
(Date:11/20/2009)... HAIFA, Israel, November 20 /PRNewswire-FirstCall...), http://www.CVSLMEDICAL.COM , a leading,develop...today announced that,the company,s Board of Direct... Europe, Canada and the Far East for its proprieta...e for all angioplasty (PCTA) procedures. , ...
(Date:11/20/2009)...ublished online November 20 in the Journal of the...ted fears and hopes that often appear in news cove...idance for both the media and journals to help all...S., and Steven Woloshin, M.D., M.S., of Center for... for Health Policy and Clinical Practice in New Ha...
Breaking Medicine News(10 mins):Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 2Health News:Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 2Health News:Just 25% of Voters in Competitive 2010 Senate Races “Much More Likely” to Support Pelosi-Democrats Who Voted for Health Care Bill 3Health News:Cardio Vascular Medical Device to Apply for Additional Patents in Europe, Canada and Far East 2Health News:Promoting healthy skepticism in the news: Helping journalists get it right 2
... of frog eyes and ears in a test tube, in the erst...ses special cells taken from frog embryos called s...o any specific type of cell in the frog's body - h...he stem cells into particular tissue. This is the ...
...can breathe a sigh of relief. A new study offers t... to increase the number of eggs a woman produces i...of ovarian cancer. // The controversy over th...ok fertility drugs and began developing ovarian ca...
...y of uterine contractions do not improve identific...tive methods such as measuring the cervix or analy...little bearing on premature birth, suggesting that...uman Development investigated whether the use of a...
...vaccinated against hepatitis B before leaving the ...infected mothers.Previously, giving the shots in t...ose mothers were known to be infected or whose dis...cs, the Centers for Disease Control and Prevention...
...the potential for depression and suicide in teens ...ay that the 15-year-old pilot who crashed his plan...is point, investigators don't know whether or not ...ccutane is very effective against severe acne, but...
...as already been shown to help prevent heart diseas...se and other types of dementia.// The study also f...ink - the effect is the same. Researchers say mode.... Besides destroying the liver, several studies ha...
Other Medicine News:Health News:Babies Need Vaccination 2
LB Agar
LB Broth (1X) liquid
...ng powder. pH: pH(4.7%, H 2 O): 7.0 0.2 Content...m Phosphate Dibasic: 25% Potassium Phosphate Monob...owder per liter of purified water. Autoclave. Appl...d recombinant proteins than LB media by allowing f...
Terrific Broth
Medicine Products: